首页> 外文期刊>Chinese journal of cancer >Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae
【24h】

Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae

机译:同期放化疗联合肠内营养支持:食管鳞状细胞癌恶性瘘管患者的根本治疗策略

获取原文
           

摘要

BackgroundConcurrent chemoradiotherapy (CCRT) significantly increases the survival rate of esophageal squamous cell carcinoma (ESCC) patients with malignant fistulae. Recent clinical evidence has shown the benefits of enteral nutrition for malnourished cancer patients. In this study, we aimed to validate that, with the support of enteral nutrition, ESCC patients who develop malignant fistulae might be able to complete CCRT and achieve long-term survival. MethodsWe reviewed the medical records of 652 patients with ESCC who received definitive CCRT at Sun Yat-sen University Cancer Center between January 2010 and December 2012. Treatment outcome and toxicity were retrospectively evaluated in 40 ESCC patients with malignant fistulae. All the 40 patients were treated with CCRT and evaluated by clinical nutritionists using nutrition risk screening (NRS) before, during, and after treatment. Twenty-two patients received a nasogastric tube, and 18 underwent percutaneous endoscopic gastrostomy feeding. The median energy intake was 2166 kcal/day. Treatment response was evaluated at 3?months after the completion of CCRT. ResultsWith a median follow-up of 18?months (range, 3–39?months), patients’ 1-year overall survival (OS) rate was 62.5%, and the estimated OS time was 25.5?months. Univariate analysis showed that the NRS score ( P =?0.003), increase in NRS score ( P =?0.024), fistula closure ( P =?0.011), and response to treatment ( P P =?0.044) and increase in NRS score ( P =?0.044) were independent predictors of OS. Grade 3 vomiting was observed in 8 patients (20.0%), grade 3 neutropenia was observed in 11 patients (27.5%), and grade 3 cough was observed in 13 patients (32.5%); 2 patients (5.0%) died of massive bleeding during treatment. ConclusionsCCRT combined with enteral nutrition support is effective for ESCC patients with malignant fistulae. Patients have an increased potential to be cured, especially those who experience complete response and have an increase in NRS score. Careful observation and nutrition support are required for patients with advanced T-category ESCC who undergo CCRT.
机译:背景同时放化疗(CCRT)可以显着提高食管鳞状细胞癌(ESCC)恶性瘘管患者的生存率。最近的临床证据表明,肠内营养对营养不良的癌症患者有益。在这项研究中,我们旨在验证在肠内营养的支持下,发生恶性瘘管的ESCC患者可能能够完成CCRT并实现长期生存。方法我们回顾了2010年1月至2012年12月在中山大学肿瘤中心接受确诊CCRT的652例ESCC患者的病历。对40例ESCC恶性瘘管患者的治疗结果和毒性进行了回顾性评估。所有40例患者均接受CCRT治疗,并在治疗之前,之中和之后由临床营养学家使用营养风险筛查(NRS)进行评估。 22例患者接受了鼻胃管,其中18例接受了经皮内镜胃造口术喂养。平均能量摄入量为2166 kcal /天。在CCRT完成后3个月评估治疗反应。结果平均随访18个月(范围3–39个月),患者的1年总生存(OS)率为62.5%,估计的OS时间为25.5个月。单因素分析显示NRS评分(P = 0.003),NRS评分增加(P = 0.024),瘘管闭合(P = 0.011)和对治疗的反应(PP = 0.044)和NRS评分增加(P = 0.014)。 P =?0.044)是OS的独立预测因子。 8例患者出现3级呕吐(20.0%),11例患者出现3级中性粒细胞减少(27.5%),13例患者出现3级咳嗽(32.5%)。 2名患者(5.0%)在治疗期间因大量出血死亡。结论CCRT联合肠内营养支持对ESCC恶性瘘管患者有效。患者治愈的可能性增加,特别是那些经历完全缓解并且NRS评分增加的患者。接受CCRT的晚期T类ESCC患者需要仔细的观察和营养支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号